177 related articles for article (PubMed ID: 28360334)
1. A Genomic DNA Reporter Screen Identifies Squalene Synthase Inhibitors That Act Cooperatively with Statins to Upregulate the Low-Density Lipoprotein Receptor.
Kerr AG; Tam LCS; Hale AB; Cioroch M; Douglas G; Agkatsev S; Hibbitt O; Mason J; Holt-Martyn J; Bataille CJR; Wynne GM; Channon KM; Russell AJ; Wade-Martins R
J Pharmacol Exp Ther; 2017 Jun; 361(3):417-428. PubMed ID: 28360334
[TBL] [Abstract][Full Text] [Related]
2. Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
Charlton-Menys V; Durrington PN
Drugs; 2007; 67(1):11-6. PubMed ID: 17209661
[TBL] [Abstract][Full Text] [Related]
3. Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway.
Do R; Kiss RS; Gaudet D; Engert JC
Clin Genet; 2009 Jan; 75(1):19-29. PubMed ID: 19054015
[TBL] [Abstract][Full Text] [Related]
4. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase.
Amin D; Rutledge RZ; Needle SN; Galczenski HF; Neuenschwander K; Scotese AC; Maguire MP; Bush RC; Hele DJ; Bilder GE; Perrone MH
J Pharmacol Exp Ther; 1997 May; 281(2):746-52. PubMed ID: 9152381
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia.
Seiki S; Frishman WH
Cardiol Rev; 2009; 17(2):70-6. PubMed ID: 19367148
[TBL] [Abstract][Full Text] [Related]
6. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors.
Tavridou A; Manolopoulos VG
Curr Pharm Des; 2009; 15(27):3167-78. PubMed ID: 19754389
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia.
Amano Y; Nishimoto T; Tozawa Ri; Ishikawa E; Imura Y; Sugiyama Y
Eur J Pharmacol; 2003 Apr; 466(1-2):155-61. PubMed ID: 12679152
[TBL] [Abstract][Full Text] [Related]
8. New lipid-lowering agents acting on LDL receptors.
Scharnagl H; März W
Curr Top Med Chem; 2005; 5(3):233-42. PubMed ID: 15857307
[TBL] [Abstract][Full Text] [Related]
9. Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase.
Ness GC; Zhao Z; Keller RK
Arch Biochem Biophys; 1994 Jun; 311(2):277-85. PubMed ID: 7911291
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis.
Tavridou A; Kaklamanis L; Megaritis G; Kourounakis AP; Papalois A; Roukounas D; Rekka EA; Kourounakis PN; Charalambous A; Manolopoulos VG
Eur J Pharmacol; 2006 Mar; 535(1-3):34-42. PubMed ID: 16545796
[TBL] [Abstract][Full Text] [Related]
11. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.
Nishimoto T; Amano Y; Tozawa R; Ishikawa E; Imura Y; Yukimasa H; Sugiyama Y
Br J Pharmacol; 2003 Jul; 139(5):911-8. PubMed ID: 12839864
[TBL] [Abstract][Full Text] [Related]
12. Squalene synthase inhibitors: An update on the search for new antihyperlipidemic and antiatherosclerotic agents.
Kourounakis AP; Katselou MG; Matralis AN; Ladopoulou EM; Bavavea E
Curr Med Chem; 2011; 18(29):4418-39. PubMed ID: 21864285
[TBL] [Abstract][Full Text] [Related]
13. Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors.
Ishihara T; Kakuta H; Moritani H; Ugawa T; Sakamoto S; Tsukamoto S; Yanagisawa I
Bioorg Med Chem; 2003 May; 11(11):2403-14. PubMed ID: 12735986
[TBL] [Abstract][Full Text] [Related]
14. Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver.
Okazaki H; Tazoe F; Okazaki S; Isoo N; Tsukamoto K; Sekiya M; Yahagi N; Iizuka Y; Ohashi K; Kitamine T; Tozawa R; Inaba T; Yagyu H; Okazaki M; Shimano H; Shibata N; Arai H; Nagai RZ; Kadowaki T; Osuga J; Ishibashi S
J Lipid Res; 2006 Sep; 47(9):1950-8. PubMed ID: 16741291
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
Ness GC; Zhao Z; Lopez D
Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
[TBL] [Abstract][Full Text] [Related]
17. Human cholesterol metabolism and therapeutic molecules.
Charlton-Menys V; Durrington PN
Exp Physiol; 2008 Jan; 93(1):27-42. PubMed ID: 18165431
[TBL] [Abstract][Full Text] [Related]
18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
19. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism.
Hiyoshi H; Yanagimachi M; Ito M; Saeki T; Yoshida I; Okada T; Ikuta H; Shinmyo D; Tanaka K; Kurusu N; Tanaka H
Eur J Pharmacol; 2001 Nov; 431(3):345-52. PubMed ID: 11730728
[TBL] [Abstract][Full Text] [Related]
20. Squalene synthetase activity in human fibroblasts: regulation via the low density lipoprotein receptor.
Faust JR; Goldstein JL; Brown MS
Proc Natl Acad Sci U S A; 1979 Oct; 76(10):5018-22. PubMed ID: 228272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
